SAN FRANCISCO — West Coast teams from Latham & Watkins and Cooley advised on the reverse merger of biopharmaceutical company Transcept Pharmaceuticals and Paratek Pharmaceuticals.
Point Richmond, Calif.-based Transcept is a publicly traded company that’s struggled to monetize an insomnia drug. Boston-based Paratek, on the other hand, is a privately held company with a Phase III antibiotic whose plans for an initial public offering were scuttled last year.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
